Search 

Respinova has developed a novel non-invasive technology that aims to treat the core of the COPD pathophysiology – small airway collapse.

Respinova's solution uses unique pulses of air pressure generated by a proprietary device called PulseHaler™. ​The small airways have no cartilage structural support and are totally dependent on the tethering forces of the surrounding lung. When these forces are diminished, the small airways collapse and do not permit airflow to the gas-exchanging alveolar zone of the lung. When COPD starts, airways initially reopen on inspiration. Once the disease progresses, the airways open only on deep inspiration, and finally not at all. When the small airways collapse, not only is gas exchange is impaired, but also the cilia clearing mechanism fails, and secretions accumulate to further worsen the situation.

The small airways have little or no smooth muscle in their walls so that neither beta-adrenergic nor muscarinic drugs can open them up, even if the particles manage to be delivered to the small airways.

The PulseHaler™ generates proprietary pressure pulses that travel into the lung which propagate faster inside the airways than in the surrounding parenchyma, thereby creating multiple momentary dilating forces that help gently pry open the collapsed airways. PulseHaler™ also generates positive pressure on exhalation, which helps with airway opening. The pulses also help in smoothing and spreading the mucus lining layer on the airways walls, which assists in airway clearance and reduces the tendency of airways to re-close.

We are rapidly transitioning to an innovation and R&D driven Pharmaceutical company, leveraging our leading manufacturing and commercial capabilities to achieve our mission of “providing today' s patients with medicines of the future“ We have been continuously recognized as one of the “Top 10 Innovative Pharmaceutical Enterprises in China” 1 and “Top 100 Pharmaceutical Manufacturing Enterprises of China”